Physician profile
Eric I Feit
NPI 1588654875
$3,647.22
in general payments reported to CMS, 2019-2025
28 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $567 · 2021: $482 · 2022: $506 · 2023: $605 · 2024: $876 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,717 · Education: $98.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,716.58 |
| Education | $98.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $584.83 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $461.50 | 2021-2024 | |
| Novo Nordisk INC | $433.54 | 2019-2025 | Ozempic |
| Astrazeneca Pharmaceuticals Lp | $381.35 | 2019-2025 | Farxiga, Andexxa, Breztri |
| Exact Sciences Corporation | $222.08 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $210.60 | 2019-2025 | |
| Allergan, INC. | $192.94 | 2020 | |
| Amgen INC. | $177.04 | 2019-2025 | Repatha, Repatha, Otezla |
| Regeneron Healthcare Solutions, INC. | $156.53 | 2021-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.19 | 2019-2024 | Jardiance |
| Genentech USA, INC. | $125.00 | 2025 | |
| Janssen Scientific Affairs, LLC | $92.41 | 2023 | Tremfya |
| Medtronic, INC. | $92.34 | 2023 | Corevalve Evolut R, Intellis Adaptivestim |
| Sumitomo Pharma America, INC. | $54.06 | 2023-2024 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $43.59 | 2024 | Voquezna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $42.68 | 2022 | |
| Depuy Synthes Sales INC. | $31.82 | 2023 | Hammerlock |
| Amarin Pharma, INC. | $27.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.14 | 2021 | |
| Janssen Pharmaceuticals, INC | $21.43 | 2020 | |
| Esperion Therapeutics, INC. | $21.37 | 2020 | |
| Almatica Pharma LLC | $20.10 | 2022 | |
| Alvogen INC | $18.71 | 2024 | Teriparatide |
| Alfasigma USA, INC. | $15.00 | 2021 | |
| Dexcom, INC. | $14.61 | 2025 | Dexcom G6 Transmitter |
| Medicure Pharma INC. | $14.28 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.29 | 2019 | |
| Eisai INC. | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Feit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.